Induction of α2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion

Oncology Reports

Volumn 17, Issue 2, 2007, Pages 417-423

  Hayashido, Yasutaka ^a   Hamana, Tomoaki ^a   Ishida, Yasutaka ^a   Shintani, Tomoaki ^a   Koizumi, Koh Ichi ^a   Okamoto, Tetsuji ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

E cadherin; Invasion; Plasminogen activator plasmin system; Squamous cell carcinoma; 2 antiplasmin

Indexed keywords

ANTIPLASMIN; CADHERIN; COLLAGEN; PLASMIN; PLASMINOGEN ACTIVATOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL ADHESION; DISEASE COURSE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MOUSE; MOUTH TUMOR; NUDE MOUSE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ANIMALS; ANTIPLASMIN; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; COLLAGEN; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; PLASMIN; PLASMINOGEN ACTIVATORS; UP-REGULATION;

EID: 33947721234     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.2.417     Document Type: Article

References (41)

1. Behrens J, Frixen U, Schipper J, Weidner M and Birchmeier W: Cell adhesion in invasion and metastasis. Semin Cell Biol 3: 169-178, 1992.
2. Weiss L and Ward PM: Cell detachment and metastasis. Cancer Metastasis Rev 2: 111-127, 1983.
3. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
4. Kemler R: Classical cadherins. Semin Cell Biol 3: 149-155, 1992.
5. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S and Takeichi M: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139: 17-23, 1991.
6. Furukawa F, Takigawa M, Matsuyoshi N, Shirahama S, Wakita H, Fujita M, Horiguchi Y and Imamura S: Cadherins in cutaneous biology. J Dermatol 21: 802-813, 1994. (Pubitemid 24380662)
7. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, Kloppel G and Lemoine NR: Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 174: 243-248, 1994.
8. Vessey CJ, Wilding J, Folarin N, Hirano S, Takeichi M, Soutter P, Stamp GW and Pignatelli M: Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol 176: 151-159, 1995.
9. Berx G, Becker KF, Hofler H and van Roy F: Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12: 226-237, 1998. (Pubitemid 28418891)
10. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153: 333-339, 1998.
11. Tryggvason K, Höyhtyä K and Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191-217, 1987. (Pubitemid 18005336)
12. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Danø K and Blichert TM: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993. (Pubitemid 23168015)
13. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997. (Pubitemid 27371946)
14. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L and Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 19: 193-207, 2002. (Pubitemid 34553521)
15. Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 291-311, 1992.
16. Testa JE and Quigley JP: The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 9: 353-367, 1990.
17. Hayashido Y, Shirasuna K and Matsuya T: Effect of epidermal growth factor on invasion of human squamous cell carcinoma cells into collagen gel. Cancer J 4: 257-261, 1991.
18. Hayashido Y, Shirasuna K, Sugiura T, Nakashima M and Matsuya T: Effect of dexamethasone on invasion of human squamous cell carcinoma cells into collagen gel. Cancer Lett 108: 81-86, 1996. (Pubitemid 26393564)
19. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
20. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM and Barlati S: Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58: 2234-2239, 1998. (Pubitemid 28232913)
21. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F and Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997. (Pubitemid 27289256)
22. Irigoyen JP, Munoz Canoves P, Montero L, Koziczak M and Nagamine Y: The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132, 1999. (Pubitemid 29471930)
23. Hayashido Y, Hamana T, Yoshioka Y, Kitano H, Koizumi K and Okamoto T: Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. Int J Oncol 27: 693-698, 2005.
24. Lijnen HR: Elements of the fibrinolytic system. Ann NY Acad Sci 936: 226-236, 2001.
25. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M and Romer J: Plasminogen activation and cancer. Thromb Haemost 93: 676-681, 2005. (Pubitemid 40485402)
26. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000. (Pubitemid 30105328)
27. Chorostowska-Wynimko J, Skrzypczak-Jankun E and Jankun J: Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 13: 759-766, 2004.
28. Yamamoto M, Sawaya R, Mohanam S, Loskutoff DJ, Bruner JM, Rao VH, Oka K, Tomonaga M, Nicolson GL and Rao JS: Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 54: 3329-3332, 1994. (Pubitemid 24225941)
29. Landau BJ, Kwaan HC, Verrusio EN and Brem SS: Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 54: 1105-1108, 1994. (Pubitemid 24085470)
30. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA and Smith HS: Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603, 1995.
31. Strojan P, Budihna M, Smid L, Vrhovec I and Skrk J: Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer 34: 1193-1197, 1998. (Pubitemid 28342108)
32. Grondahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brunner N: Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163, 1997. (Pubitemid 27165876)
33. Chambers SK, Ivins CM and Carcangiu ML: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79: 449-454, 1998. (Pubitemid 28445264)
34. Gershtein ES and Kushlinskii NE: Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med 131: 67-72, 2001. (Pubitemid 32815921)
35. Takahashi T, Suzuki K, Ihara H, Mogami H, Kazui T and Urano T: Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin. Semin Thromb Hemost 31: 356-363, 2005. (Pubitemid 40962399)
36. Palmieri D, Lee JW, Juliano RL and Church FC: Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 277: 40950-40957, 2002. (Pubitemid 35215683)
37. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad O and Engebraaten O: Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res 294: 130-139, 2004. (Pubitemid 38229787)
38. Aoki N: The past, present and future of plasmin inhibitor. Thromb Res 116: 455-464, 2005.
39. Coughlin PB: Antiplasmin: the forgotten serpin? FEBS J 272: 4852-4857, 2005.
40. Sugiura T, Shirasuna K, Hayashido Y, Sakai T and Matsuya T: Effects of human fibroblasts on invasiveness of oral cancer cells in vitro: isolation of a chemotactic factor from human fibroblasts. Int J Cancer 68: 774-781, 1996. (Pubitemid 27062040)
41. Hayashido Y, Lucas A, Rougeot C, Godyna S, Argraves WS and Rochefort H: Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer 75: 654-658, 1998. (Pubitemid 28094116)